Showing 6791-6800 of 9552 results for "".
- Bristol Myers Squibb's Deucravacitinib Performs Well in Phase 2 Study in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/bristol-myers-squibbs-deucravacitinib-performs-well-in-phase-2-study-in-patients-with-psoriatic-arthritis/2460605/Results from an ongoing Phase 2 study evaluating the safety and efficacy of Bristol Myers Squibb's deucravacitinib (BMS-986165) 6mg or 12mg once daily, compared with placebo in
- Two New Studies Suggest Age Is A Primary Determinant Of Melanoma Treatment Resistancehttps://practicaldermatology.com/news/two-new-studies-suggest-age-is-a-primary-determinant-of-melanoma-treatment-resistance/2460595/Age is a primary factor in treatment response in animal and laboratory models of melanoma cells, according to two new studies. The new findings by Johns Hopkins Kimmel Cancer Center and
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi
- AbbVie Presents Additional Phase 3 Data for Upadacitinibhttps://practicaldermatology.com/news/abbvie-presents-additional-phase-3-data-on-upadacitinib/2460591/Significantly more patients treated with AbbVie’s upadacitinib in both of the Measure Up 1 and 2 studies
- New Government Advisory Cites Risk for Ransomware Attacks on Healthcare Systemhttps://practicaldermatology.com/news/new-government-advisory-cites-risk-for-ransomware-attacks-on-healthcare-system/2460587/A new advisory coauthored by the Cybersecurity and Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), and the Department of Health and Human Services (HHS) warns of the potential for ransomware attacks against hospitals and medical systems. “CI
- Where is the Hydroquinone? Regulatory Change Hinders Accesshttps://practicaldermatology.com/news/where-is-the-hydroquinone-regulatory-change-hinders-access/2460586/Changes to FDA regulations implemented as part of the CARES Act this spring have left dermatologists and their patients scrambling to access hydroquinone. Although access is hindered, it is not cut off. “I think most people at this point are familiar with the CARES Act. What they
- FDA Grants Priority Review for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe ADhttps://practicaldermatology.com/news/fda-grants-priority-review-for-pfizers-abrocitinib-an-oral-once-daily-jak1-inhibitor-for-patients-12-and-up-with-moderate-to-severe-ad/2460580/The U.S. Food and Drug Administration (FDA) has granted Priority Review designation to Pfizer’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in
- New from BTL: Emsculpt NEO Launcheshttps://practicaldermatology.com/news/new-from-btl-emsculpt-neo-launches/2460571/The first procedure to combine radio frequency heating and high-intensity focused electromagnetic waves into a single therapy, Emsculpt NEO from BTL, has launched. It is FDA-cleared to eliminate fat cells non-invasively. Emsc
- DermOQ To Buy Skin Products's ECHO2 Plus Oxygen Facial Treatment Product Linehttps://practicaldermatology.com/news/dermoq-to-buy-skin-products-incs-echo2-plus-oxygen-facial-treatment-product-line/2460569/DermOQ Inc. is purchasing Skin Products Inc.’s ECHO2 Plus and Oxyceuticals oxygen facial treatment product lines. DermOQ offers its topical oxygen products under the brand names DermOQ Oxygen Lab and
- Coverage Update: Cigna to Cover Excimer Laser Treatment for Vitiligohttps://practicaldermatology.com/news/coverage-update-cigna-to-cover-excimer-laser-treatment-for-vitiligo/2460566/Cigna, a global health services company offering health, pharmacy, dental and Medicare plans to both individuals and businesses covering over 20 million people in the United States, has issued a new medical coverage policy for excimer laser therapy vitiligo. STRATA Skin Sciences, maker of the XTR